HDAC9 and Friedreich ataxia: Furthermore, by generating hCBOs from patients with Friedreich’s ataxia (FRDA), we revealed abnormal disease-specific phenotypes that could be reversed by histone deacetylase (HDAC) inhibitors and gene editing by CRISPR-Cas9.